FGFR2 and metastatic malignant neoplasm: The ReFocus trial (NCT04526106), a phase 1/2 open label global study, is currently evaluating the safety and efficacy of RLY-4008 in patients with advanced unresectable and/or metastatic cancers harbouring an FGFR2 alteration [50].